|
CTDSP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.0087043139938E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.28779999997164E-08 |
| Normal-vs-Stage2 |
1.90910000030797E-07 |
| Normal-vs-Stage3 |
4.1004999395966E-10 |
| Normal-vs-Stage4 |
7.03140001778735E-09 |
| Stage1-vs-Stage2 |
3.534600E-01 |
| Stage1-vs-Stage3 |
2.444400E-01 |
| Stage1-vs-Stage4 |
1.716640E-01 |
| Stage2-vs-Stage3 |
8.810400E-01 |
| Stage2-vs-Stage4 |
9.091000E-01 |
| Stage3-vs-Stage4 |
7.668000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.43509998224079E-10 |
| Normal-vs-AfricanAmerican |
1.382880E-04 |
| Normal-vs-Asian |
2.440700E-04 |
| Caucasian-vs-AfricanAmerican |
8.417400E-01 |
| Caucasian-vs-Asian |
2.069600E-01 |
| AfricanAmerican-vs-Asian |
4.774600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.10510514470275E-11 |
| Normal-vs-Female |
5.27889953971794E-10 |
| Male-vs-Female |
1.828030E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.64829999941219E-08 |
| Normal-vs-Age(41-60Yrs) |
6.53370002545728E-09 |
| Normal-vs-Age(61-80Yrs) |
1.27799992810651E-10 |
| Normal-vs-Age(81-100Yrs) |
1.424140E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.731200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.481700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.859200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.158830E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.058400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.286200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.497800E-01 |
| Classical-VS-Follicular |
7.580300E-04 |
| Classical-VS-Other |
2.494600E-01 |
| Classical-VS-Normal |
6.56520005026806E-09 |
| Tall-VS-Follicular |
9.621700E-02 |
| Tall-VS-Other |
4.844000E-01 |
| Tall-VS-Normal |
1.43439999999995E-06 |
| Follicular-VS-Other |
8.647800E-01 |
| Follicular-VS-Normal |
4.37500036198912E-10 |
| Other-VS-Normal |
4.103200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.35043145741565E-12 |
| Normal-vs-N1 |
1.70230000096083E-08 |
| N0-vs-N1 |
6.690400E-01 |
|
|
